» Articles » PMID: 6835125

The Effect of Cessation of Smoking on the Accumulative Survival Rates of Patients with Symptomatic Peripheral Vascular Disease

Overview
Journal Med J Aust
Specialty General Medicine
Date 1983 Mar 5
PMID 6835125
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

A study of the accumulative survival rates of 133 patients with symptomatic peripheral vascular disease was carried out comparing the survival rates of tobacco smokers and non-smokers. Within the smoking group, those who continued to smoke after the surgery were compared to those who ceased smoking. Of these patients with peripheral vascular disease, 86% were, or had been, smokers. Their survival rates were less than for those who had never been smokers. Of the smoking group, those who claimed to have ceased smoking had almost twice the chance of surviving five years than those who continued to smoke. From these data, we conclude that it is never too late to stop the smoking habit.

Citing Articles

Sex and Racial Disparities in Peripheral Artery Disease.

Divakaran S, Krawisz A, Secemsky E, Kant S Arterioscler Thromb Vasc Biol. 2023; 43(11):2099-2114.

PMID: 37706319 PMC: 10615869. DOI: 10.1161/ATVBAHA.123.319399.


Medical Management of Peripheral Artery Disease.

Holder T, Gutierrez J, Aday A Cardiol Clin. 2021; 39(4):471-482.

PMID: 34686260 PMC: 8544815. DOI: 10.1016/j.ccl.2021.06.001.


Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines.

Bath J, Lawrence P, Neal D, Zhao Y, Smith J, Beck A J Vasc Surg. 2020; 73(5):1693-1700.e3.

PMID: 33253869 PMC: 8189641. DOI: 10.1016/j.jvs.2020.10.067.


On the Cutting Edge: Wound Care for the Endovascular Specialist.

Olivieri B, Yates T, Vianna S, Adenikinju O, Beasley R, Houseworth J Semin Intervent Radiol. 2019; 35(5):406-426.

PMID: 30728657 PMC: 6363558. DOI: 10.1055/s-0038-1676342.


Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).

Pagidipati N, Navar A, Pieper K, Green J, Bethel M, Armstrong P Circulation. 2017; 136(13):1193-1203.

PMID: 28626088 PMC: 5614823. DOI: 10.1161/CIRCULATIONAHA.117.027252.